More than half of patients with a rheumatic disease or immunologic condition undergoing methotrexate treatment reside in states in which the overturning of Roe v. Wade can jeopardize access to medications with abortifacient potential

Arthritis Rheumatol. 2023 Feb;75(2):328-329. doi: 10.1002/art.42398. Epub 2022 Dec 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortifacient Agents*
  • Health Services Accessibility
  • Humans
  • Immune System Diseases*
  • Methotrexate / therapeutic use
  • Rheumatic Diseases* / drug therapy
  • United States

Substances

  • Methotrexate
  • Abortifacient Agents